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The Influence of Apathy and Depression on Cognitive Functioning  
in Parkinson’s Disease 
 
London C. Butterfield 
 
ABSTRACT 
 
Depression and apathy are two of the most common psychiatric symptoms in 
Parkinson’s disease (PD) with prevalence estimates at higher rates than in medical 
populations with similar levels of disability. Several studies have provided evidence to 
suggest that apathy and depression are independent clinical phenomena that may 
differentially affect cognition. Recent research suggests that apathy may account for 
cognitive deficits over and above that of depression, especially in the domain of 
executive functioning. However, few studies have examined the independent influence of 
depression and apathy on cognitive abilities in patients diagnosed with PD using sensitive 
measures of specific cognitive domains. In addition, many have used measures of apathy 
and/or depression with symptom overlap, which may not adequately measure symptoms 
unique to the target construct. 
The purpose of this study was to examine the independent influences of 
symptoms of depression and apathy on memory and executive functioning in patients 
diagnosed with PD using severity scales specifically designed to provide greater 
discrimination between symptoms. Depression severity was assessed using items that do 
not overlap with apathy symptoms or with somatic symptoms of PD itself. Apathy was 
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measured using a scale previously shown to have little overlap with depressive 
symptoms.  
Results revealed that apathy, but not depression, was significantly associated with 
executive functioning. In contrast, immediate memory was significantly associated with 
both apathy and depression. However, apathy accounted for added variance in memory 
scores when controlling for depression with marginal significance. When controlling for 
age, although less clear, these patterns remained.   
Differentiation of apathy and depression and understanding their independent 
effects on cognitive functioning have several implications both for clinical intervention 
and for scientific investigation. Apathy not only has a negative impact on cognitive 
functioning, but also on daily functioning and caregiver burden/distress. Secondly, it has 
been associated with increased mortality as it may interfere with medication compliance. 
If appropriately identified, preliminary research suggests that symptoms of apathy may be 
medically treated independently of depressive symptoms. Distinguishing apathy and 
depression has robust implications for the advancement of psychological science, patient 
care, and for enhancing quality of life in patients and caregivers.  
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1. Introduction 
 
 Parkinson’s Disease (PD), a chronic and degenerative neurological disorder, 
affects approximately one million people over the age of fifty in the United States alone. 
While motor dysfunction is most apparent in PD, psychiatric symptoms have been 
reported to occur in as many as 90% of PD patients (Starkstein, Mayberg, Leiguarda, 
Preziosi, and Robinson, 1992b), with depression being the most common symptom. 
Prevalence estimates of clinically elevated depression average at around 40% in this 
population (Cummings, 1992), compared to 4-6% of older adults in the general 
population (Steffens et al., 2000). Apathy, a symptom related to motivational and self-
initiation impairment, is also elevated in PD and other disorders involving the basal 
ganglia, with an average estimated prevalence of 40.6% (van Reekum, Stuss, and 
Ostrander, 2005). Again, this is higher than found in the general population, where the 
prevalence of clinically elevated apathy is estimated at 6.8% in older adults (Onyike et 
al., 2007). Psychiatric symptoms may negatively impact several patient variables, 
including daily functioning, cognitive functioning, and quality of life and may 
additionally impact caregiver burden and distress (Shrag, Jahanshahi, and Quinn, 2000; 
Chen, 2004; Keranen et al., 2003; Gote, 1999).  
Several studies suggest that apathy and depression are independent clinical 
phenomena that negatively affect memory, language, and executive functioning 
(Starkstein et al., 1992a; Pluck and Brown, 2002; Isella et al, 2002; Feil, Razani, Boone, 
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and Lesser, 2003). Recent research suggests that apathy may account for cognitive 
deficits over and above that of depression. Few studies have investigated the independent 
influence of depression and apathy on cognitive abilities in patients diagnosed with PD. 
Further, the few studies that have examined these relationships have used simple 
screening measures of global cognitive ability that are insensitive to specific cognitive 
domains.  
The present study will attempt to enhance our understanding of the independent 
influences of depression and apathy on memory and executive functioning in patients 
diagnosed with PD using sensitive and more specific cognitive measures. Hierarchical 
regression will allow for examination of the influence of depression on cognitive 
performance while controlling for the independent influence of apathy, and vice versa. 
Before providing a detailed account of the methodological plan for the present study, an 
introduction to PD and a review of the literature that has examined the relationships 
between depression, apathy, and cognition in this population is provided.     
 
Parkinson’s Disease 
 First described as the “shaking palsy” by James Parkinson in 1817 (Parkinson, 
1817), Parkinson’s Disease (PD) has since become prevalent worldwide, occurring in an 
estimated 1% of people over the age of fifty, or about one million people, in the United 
States alone (Stern, 1993). Most cases of PD present after the age of 50, with a mean age 
of onset at 55 to 60 years (Mackin, 2000; Stern, 1993). Few cases, if any, appear after the 
age of 80 (Mackin, 2000). Although the exact cause of PD remains unknown, there are 
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several theorized causes of the disorder. These include toxic exposures (environmental, 
occupational, or drug induced), oxidative stress, and genetics. Most cases of PD are 
considered idiopathic, or of unknown cause.  
 PD is a chronic, progressive neurodegenerative disorder marked by slow 
degeneration of dopaminergic neurons primarily in the substantia nigra. The depletion of 
dopamine interferes largely with the nigrostriatal pathway of the basal ganglia, a system 
largely implicated in the production of movement and coordinated muscle control (Gibb, 
1992). PD patients have lost at least 60-70% of their dopamine-producing cells by the 
time motor symptoms appear (Fearnley and Lees, 1991). Although dopamine and the 
nigrostriatal pathway are primarily affected, there is evidence of disruption to other brain 
regions (e.g. locus ceoruleus, specific reticular nuclei) and circuits (e.g., mesolimbic 
pathway) as well, resulting in noradrenergic, serotonergic, and cholinergic abnormalities 
of the basal ganglia (Lang and Lozano, 1998, Mackin, 2000). Decreased dopamine in the 
mesolimbic pathway, a system related to reward sensitivity, may contribute to psychiatric 
symptoms of depression and apathy (Lieberman, 2006; Fibiger, 1984).  
 The classic triad of motor signs in PD include resting tremor, rigidity, and 
bradykinesia/akinesia (Lang and Lozano, 1998). Resting tremor is the most common and 
identifiable sign of disease, being the initial complaint in approximately 70% to 75% of 
cases (Stern, 1993). Tremors often occur in the hands, fingers, forearms, foot, mouth, or 
chin, and take place when the limbs are at rest. When the patient voluntarily initiates 
movement, however, the tremor subsides. Rigidity refers to muscle stiffness that occurs, 
also called cogwheeling, which can result in muscle pain or discomfort during movement. 
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Bradykinesia refers to the slowness of voluntary movement, such as standing up, 
walking, and sitting down, that occurs because of delayed transmission signals from the 
brain to the muscles. Parkinson’s gait, characterized by a shortened stride, and shuffling 
steps, is a common feature. Other primary motor symptoms include postural instability, 
or poor balance, and other coordination impairment. In later stages of the disease, 
akinesia (lack of voluntary movement), festination (more severe and abnormal gait 
pattern), hypophonia (voice weakness), dysarthria (speech impairment), chewing and 
swallowing difficulties, as well as drooling can occur (Mackin, 2000).  
 Symptom progression varies by individual but typically progresses over a period 
of 10 to 20 years (Langston, 1990). Progression can be divided into three states: early, 
nonfluctuating, and fluctuating (Bradley, 1996). Patients in the early stage of disease may 
be monosymptomatic or have multiple mild symptoms that do not need medication 
management, with symptoms typically presenting unilaterally. In the nonfluctuating 
stage, symptoms become disabling and may not respond to first-line therapy. Once 
patients have reached the fluctuating stage of disease, continual progression of symptoms 
has occurred and control over symptoms fluctuates. Postural instability and gait 
disturbance is increased and function has become more impaired despite therapy.      
 While motor dysfunction is typically the most apparent in PD, psychiatric 
symptoms are also prevalent and have been reported to occur in as many as 90% of PD 
patients (Starkstein et al., 1992b). Depression is the most common psychiatric symptom 
with apathy, anxiety, sleep disturbance, and hallucinations occurring at high rates as well. 
Hallucinations are commonly attributable to anti-Parkinson’s medications and are 
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typically visual and benign in nature (Mackin, 2000). Psychiatric symptoms have a 
significant negative impact on daily functioning, quality of life, cognitive functioning and 
caregiver burden and distress (Shrag, Jahanshahi, and Quinn, 2000; Chen, 2004; Keranen 
et al., 2003).  
 Mental decline affects up to 90% of patients (Pirozzolo, Hansch, Mortimer, 
Webster, and Kuskowski, 1982). In contrast, severe cognitive impairment is less frequent, 
affecting approximately 25% of patients, as most symptoms are subtle and do not 
interfere significantly with everyday activities (Mayeux et al., 1990; Stocchi and Brusa, 
2000). Characteristic cognitive changes in PD include impairment in attention, 
abstraction and reasoning, visuospatial abilities, executive functions, and memory 
(Stocchi and Brusa, 2000).  
The greatest area of difficulty for PD patients involves executive functions. These 
mental operations are involved in adapting to novel situations, problem solving, planning, 
generating new concepts and elaborating cognitive and behavioral responses to 
environmental situations (Stocchi and Brusa, 2000). Tests commonly used to evaluate 
executive functions include Trail Making Test, Stroop test, letter fluency (e.g., FAS), 
Tower of London for problem solving, and Wisconsin Card Sorting Test (WCST).  
Regarding memory disturbance, impairment may be found in working memory, 
immediate recall, and delayed recall. Research has shown that PD patients have more 
pronounced impairments on immediate memory tasks compared to delayed memory tasks 
(Sagar, Cohen, Sullivan, Corkin, and Growdon, 1988). The ability to register, store, and 
consolidate data appears preserved; however, the recall deficit is due to impairment in the 
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ability to activate processes that are associated with the functional use of memory stores 
(Stocchi and Brusa, 2000). Long-term memory is impaired due to a decrease in 
attentional resources rather than decreased storage (Pillon, Dubois, and Agid, 1996). This 
decreased attentional capacity interferes with organizing material to be remembered, 
temporal ordering, and memory retrieval strategies (Harrington, Haaland, Yeo, and 
Marder, 1990).  
Visuospatial disturbance may also be present in PD, but results from a decrease in 
processing resources rather than from a specific visuospatial dysfunction (Brown and 
Marsden, 1986).       
 
Depression in PD 
Depression is the most common psychiatric symptom in PD, and is found at 
higher rates in this population than in medical populations with similar levels of 
disability, such as rheumatoid arthritis (Brown and Jahanshahi, 1995; Cummings and 
Masterman, 1999; Zesiewicz and Hauser, 2000). Prevalence estimates of depression in 
PD range from 3 to 70% (Cummings, 1992; Burn, 2002), although most estimates are 
closer to 40%, with just over half meeting criteria for major depression and just under 
half meeting criteria for dysthymia or minor depression (Cummings, 1992). The 
variability reported across studies is partially dependent upon heterogeneous samples 
used (e.g., hospitalized, community-based) as well as the research tools used to measure 
depression, with lower rates generally reported in studies that include diagnostic criteria 
and scripted interviews (e.g., Structure Clinical Interview for the DSM-IV, SCID) 
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compared to studies using rating scales (e.g., Beck Depression Inventory, BDI; Beck et 
al., 1961, 1996) (Edwards et al., 2002).  
Symptom overlap also contributes to the variability in prevalence estimates. 
Symptoms of depression, primarily somatic [e.g., psychomotor retardation, flat affect, 
“masked facies” (reduced facial expression of emotion), anergia], often overlap with core 
features of PD (Edwards et al., 2002), and may lead to an over-estimation of depression 
in patient samples. Most prevalence studies in research centers find depression in 40% to 
50% of PD patients (Edwards et al., 2002; Mayeux, Stern, Williams, Sano, and Cote, 
1986; der Gotham, Brown, and Marsden, 1986), with half meeting criteria for major 
depressive disorder (MDD) and half meeting criteria for dysthymia or minor depression 
(Starkstein, Preziosi, Bolduc, and Robinson, 1990b; Brown and MacCarthy, 1990).  
 Research studies that use diagnostic criteria in identifying levels of depression 
typically define major and minor depression using criteria of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM). According to the most recent edition of 
the DSM (i.e., DSM-IV-TR; APA, 2000) major depression is defined by the presence of 
five or more of the following symptoms during the same two-week period and 
representing a change from previous functioning, with at least one of the symptoms being 
(1) or (2):  
(1) depressed mood 
(2) markedly diminished interest or pleasure in all, or almost all, activities  
(3) significant weight loss when not dieting or weight gain, or decrease in appetite  
(4) insomnia or hypersomnia 
(5) psychomotor agitation or retardation  
(6) fatigue or loss of energy 
(7) feelings of worthlessness or excessive or inappropriate guilt 
(8) diminished ability to think or concentrate, or indecisiveness 
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(9) recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation 
without a specific plan, or a suicide attempt or a specific plan for committing 
suicide 
 
As for minor depression, depressive symptoms must be present for at least two weeks but 
fewer than five symptoms are required. 
 Depression in PD differs from idiopathic depression in that PD patients 
experience relatively increased levels of dysphoria and pessimism about the future, 
irritability, sadness and suicidal ideation, while guilt, self-blame, feelings of failure, and 
completed suicide are less common (Brown, MacCarthy, Der Gotham, and Marsden, 
1988; Taylor, Saint-Cyr, Lang, and Kenny, 1986). Depression in PD is an important issue 
to address as these patients have more rapid disease progression, increased cognitive 
decline, increased functional disability, and poorer quality of life than PD patients 
without depression (Sano et al., 1989; Starkstein et al., 1992b; Cole et al., 1996).  
 It remains unclear whether PD patients have a biological vulnerability to 
depression, or whether depression is a reaction to disability. In support of the former 
hypothesis, Schuurman et al. (2002) found an increased incidence of PD in patients with 
a prior history of depression, perhaps reflecting a biological risk factor for depression in 
still symptom-free, preclinical stages of PD.  Other studies also support that symptoms of 
depression often precede motor symptoms and the diagnosis of PD (Brown and 
Jahanshahi, 1995; Cummings and Masterman, 1999).  
Hypotheses for the etiology of depression in PD tend to favor neurodegeneration 
as the primary source (Tandberg, Larsen, Aarsland, Laake, and Cummings, 1997; 
Cummings and Masterman, 1999). Evidence exists to suggest that dopamine, serotonin, 
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and norepinephrine play an important role in depression (e.g., Cummings and 
Masterman, 1999; Zesiewicz, Gold, Chari, and Hauser, 1999). PD patients who 
experience the ‘on-off’ phenomenon (i.e., fluctuations in motor symptoms that are 
associated with response to medication), for instance, complain of a greater level of 
depression during the ‘off’ state, when dopamine levels are low and motor symptoms are 
more severe (Menza, Sage, Marshall, Cody, and Duvoisin, 1990). Several studies have 
found lower levels of 5-hydroxyindoleacetic acid, the principal metabolite of serotonin, 
in PD patients with depression as compared to PD patients without depression (e.g., 
Sjostrom and Ross, 1973; Ashcroft et al., 1966). In addition, norepinephrine levels are 
more markedly decreased in PD patients with depression as compared to those without 
depression (Lieberman, 2006). In PD, each of these neurotransmitter systems is disrupted 
and may underlie the high rates of depression as well as the cognitive impairment that is 
experienced.  
 
Depression and Cognition in PD 
 Prior studies of PD patients indicate that depression has an adverse impact on 
cognitive functioning and may serve as a risk factor for cognitive decline. One 
epidemiologic study revealed that depression was a significant and independent predictor 
of incident dementia in PD (Stern, Marder, Tang, and Mayeax, 1993). In the first 
longitudinal study to investigate the influence of depression on cognitive decline in PD, 
Starkstein and colleagues (Starkstein, Bolduc, Mayberg, Preziosi, and Robinson, 1990a) 
found that patients who were depressed at baseline showed significantly greater decline 
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in global cognitive functioning (i.e., MMSE score) at a three- to four-year follow-up as 
compared to PD patients who were not depressed at baseline.  
In a later study, Starkstein et al. (1992b) divided depressed PD patients into two 
groups: (1) those meeting DSM-III criteria for major depression, and (2) those meeting 
DSM-III criteria for minor depression. At one year follow-up, patients with major 
depression at baseline evaluation showed significantly greater decline in global cognitive 
functioning than those with minor depression or no depression at baseline. Patients were 
matched for duration of illness and disability severity in order to control for the 
possibility that these disease factors, rather than depression, were accounting for the 
cognitive declines. 
 In a series of studies, Tröster and colleagues built upon the literature to further 
investigate the relationship between depression and cognition in PD (i.e., Tröster, 1995a; 
Tröster, 1995b; Norman, Tröster, Fields, and Brooks, 2002). First, they compared PD 
patients with depression (PDD) and without depression (PDN) to normal control (NC) 
subjects matched for age, education, gender, disease duration, age of disease onset, and 
disease severity to find that both PD groups (PDD and PDN) showed greater impairment 
on a screening measure of global cognitive ability (i.e., Mattis Dementia Rating Scale, 
DRS), with particular impairments on Conceptualization and Initiation/Perseveration 
subscales, as compared to NC subjects. PDD patients performed significantly worse than 
PDN patients (Tröster, 1995a). To follow, they used a more extensive battery of 
neurocognitive assessments to evaluate the qualitative difference in cognitive abilities 
between PDD and PDN patients (Tröster, 1995b). Results suggested that depression 
11 
 
exacerbated some memory and language impairments previously associated with PD and 
that depression influences the severity rather than the quality, or pattern, of cognitive 
impairment in PD.  
 In a third study, these researchers (Norman et al., 2002) added a comparison 
group of subjects with depression but without PD (D) that would allow them to determine 
whether the previously identified cognitive impairments were due to a combined effect of 
PD and depression or to depression alone. This is important since the same frontal 
metabolic changes that may be strongly related to cognitive impairment are found in 
depressed individuals regardless of having a PD diagnosis (Dolan et al., 1994; Norman et 
al., 2002). Results revealed poorer overall cognitive functioning (i.e., DRS total) in both 
PD groups (PDD and PDN) as compared to non-PD groups (NC and D). Interestingly, 
both depressed groups (D and PDD) performed more poorly on the Memory subscale as 
compared to PDN patients, suggesting that the memory impairment found in PDD 
patients may be a result of depression alone as opposed to a combined effect of 
depression and PD.    
 In a similar study, Kuzis and colleagues (1997) found that patients with 
depression, with or without PD, showed significantly greater impairment on verbal 
executive (fluency) ability and auditory attention as compared to those who were non-
depressed (PDN and NC). PDD patients were significantly more impaired than the other 
three groups on concept formation (i.e., Raven Progressive Matrices) and set shifting 
(Wisconsin Card Sorting Test), a measure of executive functioning. Further, no 
differences in cognitive performance were found between PDN patients and NC subjects.  
12 
 
 In sum, the presence of depression in PD may exacerbate existing cognitive 
deficits on tasks such as concept formation, memory, language, and executive 
functioning. 
 
Apathy in PD 
 In contrast to depression, apathy and abulia (a more severe form of apathy) are 
not characterized by anhedonia, hopelessness, or low mood; rather, they are characterized 
by isolated lack of motivation and self-initiative (Shrag, 2004). The study of apathy as a 
neuropsychiatric construct in neurological disorders has only recently begun, with its 
initiation in 1990 (Marin, 1990; Marin, Biedryzycki, and Firinciogullari, 1990; Burns, 
Folstein, Brandt, and Folstein, 1990; Robinson and Starkstein, 1990). Apathy, derived 
from the Greek term pathos, meaning passions, is conventionally defined as the absence 
or lack of emotion, feeling, interest, or concern (Marin, 1990, 1991). Clinically, this 
definition of apathy is lacking and fails to address a variety of other psychological 
features. Individuals with frontal lobe injury, for instance, may be experiencing apathy 
along with some other intense emotion, such as irritability or euphoria. Similarly, a 
depressed individual may appear to be “lacking emotion, interest, and concern,” while 
s/he is indeed experiencing severe internal emotional pain.  
Marin provided a more clinically appropriate definition of apathy as a primary 
motivational impairment that is, importantly, not secondary to cognitive or intellectual 
impairment, emotional distress, or diminished level of consciousness (drowsiness and/or 
diminished attention) (Marin, 1990, 1991). One who meets this definition of apathy may 
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be regarded as having apathy syndrome. Loss of motivation due to disturbance of intellect 
(e.g., dementia), emotion (e.g., depression), or level of consciousness (e.g., delirium) 
defines the symptom of apathy (Marin, 1991). Motivation itself refers to characteristics 
and determinants of goal-directed behavior (Marin, 1991). 
Stuss et al. (2000) revised the definition of apathy as “an absence of 
responsiveness to stimuli as demonstrated by a lack of self-initiated action,” suggesting 
that this definition would allow for objective behavioral measurement. They proposed 
that previous conceptualizations of apathy as a lack of motivation were flawed in that 
assessment of inner urges is problematic and necessitates inference based on observations 
of affect and behavior. 
Marin (1991) proposed that symptoms of apathy can be classified into three 
concomitants of goal-directed behavior: “emotional” (i.e., lack of emotional 
responsiveness; lack of excitement or emotional intensity; unchanging affect), 
“cognitive” (i.e., lack of interest; lack of concern about one’s personal problems; 
diminished importance or value attributed to various goal-related domains), and “(overt) 
behavioral” (i.e., lack of effort; lack of initiative or perseverance; compliance or 
dependence on others to structure activity).  
Since apathy itself may be considered as behavioral (i.e., an observable state), 
Levy and Dubois (2005) refer to the third domain as an “auto-activation deficit” that is 
not primarily due to an “emotional” or “cognitive” deficit and can be reversed by external 
stimulation. They proposed that the three concomitants of apathy (i.e., emotional-
affective, cognitive, and auto-activation of behavior) may each be explained by 
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disruption to three underlying mechanisms and their associative basal ganglia subregions: 
orbital-medial, dorsal-lateral, and dorsal-medial streams. Amotivational symptoms are 
reported in several cases of frontal impairment (i.e., stroke, degeneration, head injury) 
and frontal-subcortical limbic dysfunction (i.e., PD, AD, stroke) and may underlie 
associated executive functioning deficits (Isella et al., 2002).  
PD is a classic example of a subcortical disorder in which apathy is a well-
recognized feature (Isella et al., 2002; Pluck and Brown, 2002; Aarsland et al., 1999; 
Starkstein et al., 1993, 1995; Marsden and Parkes, 1977) and it is hypothesized that 
nigrostriatal dopamine depletion in PD may contribute (Levy and Dubois, 2005). 
Clinically significant apathetic symptoms are present in approximately 40% to 45% of 
PD patients (Isella et al., 2002; Starkstein et al., 1992a), compared to 6.8% in healthy 
older adults (Onyike et al., 2007), with apathetic syndromes (not secondary to depression, 
delirium, or dementia) present in about 12% of PD patients (Starkstein et al., 1992a).   
Apathy appears to be a result of neurological disturbance rather than a result of 
psychosocial limitations of physical disability. Pluck and Brown (2002) showed that, 
while PD and osteoarthritis are similarly chronic, progressive conditions that cause 
significant levels of disablement, significant levels of apathy were found in PD patients, 
but no evidence of apathy was present in osteoarthritic patients. Isella et al. (2002) 
showed that groups of patients with low, moderate, and high levels of apathy did not 
differ from each other in PD duration or severity, suggesting that apathy unlikely 
represents a simple reaction to disability. These findings together have been provided as 
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support for the view that apathy is not a psychological response to physical disability, but 
rather a neurobiological feature of PD. 
Some hypotheses suggest that apathy and depression are related to distinct 
neurological circuits, with depression being secondary to dysfunction of brainstem 
serotoninergic neurons (i.e., raphe nuclei) that project to limbic areas, and apathy derived 
from the noradrenergic deficit at the locus coeruleus (connected with cortical and 
subcortical structures) (Starkstein et al., 1992a; Mayeux et al., 1987). Marin (1990, 1991; 
also see Isella et al., 2002) suggested that a frontal-subcortical limbic circuit (i.e., 
prefrontal cortex, anterior cingulate gyrus, entorhinal cortex, and the basal ganglia), 
which seems to play a central role in conveying emotionally relevant information, 
elaborating drive, and in planning and monitoring motivated behavior, may mediate the 
association found between apathy and executive functioning. Dysfunction of this region 
may result in executive deficits, amotivation, and/or of the capacity to organize goal-
directed behavior.  
 
Apathy and Depression: Independent Clinical Phenomena 
While certain symptoms may be shared among apathy and depression (i.e., 
diminished interest, psychomotor retardation, fatigue/hypersomnia, lack of insight), 
several researchers have suggested that certain symptoms are unique to apathy (i.e., 
blunted affect, indifference, low social engagement, diminished initiation, poor 
persistence) and certain symptoms are unique to depression (i.e., dysphoria, suicidal 
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ideation, self-criticism, feelings of guilt, pessimism, hopelessness, sleep disturbance) 
(Marin et al., 1993, Marin 1990, Landes et al., 2001). 
Various methods have been employed to examine the discriminability of apathy 
and depression as independent clinical phenomena. Depression is a syndrome in which 
apathy may be present, in which case it may be termed apathetic depression (Marin, 
1990). In this instance, a depressed person’s apathy may be described by a person’s 
inactivity and expressed loss of interest in usual activities. However, there are several 
instances in which depression may exist in the absence of apathy. In the case of the 
depressed person who demonstrates deliberate and active avoidant behavior, or in the 
extreme case of suicide, clearly apathy (which describes passivity or a lack of goal-
directed behavior) is not an accurate descriptor (Marin, 1990). Further, apathy may exist 
as a distinct syndrome, in which, by definition, there is absence of emotional distress.  
Weitzner, Kanfer, and Booth-Jones (2005) described four cases of pituitary 
disease patients who appeared to be suffering from depression, but when diagnosed and 
treated for depression they showed little response to treatment. When the patients were 
asked about their mood, all stated that they were experiencing chronic fatigue and lack of 
motivation, and were not feeling depressed. When the diagnosis of apathy syndrome was 
considered and treatment with methylphenidate was implemented, the patients’ condition 
improved subjectively and on objective cognitive tasks (i.e., verbal and nonverbal 
learning, several executive tasks, and psychomotor speed).  
One method of distinguishing apathy and depression is to evaluate the rates and 
relationships between apathy and depression in different diagnostic groups. Marin et al. 
17 
 
(Marin, Firinciogullari, and Biedrzycki, 1994) evaluated patients diagnosed with 
Alzheimer’s disease (AD), stroke, and major depression using the Apathy Evaluation 
Scale (AES; Marin, Biedrzycki, and Firinciogullari, 1991) and the Hamilton Depression 
Rating Scale (HDRS; Hamilton, 1960). Despite the fact that there was a significant 
correlation found between apathy and depression scores when all five diagnostic groups 
were included in the analysis, proportions of patients with apathy and/or depression 
varied considerably among groups. Specifically, AD patients showed high levels of 
apathy and low levels of depression, left hemisphere stroke patients and patients with 
major depression showed high levels of depression and low levels of apathy, and patients 
with right hemisphere stroke showed equivalent levels of apathy and depression. The 
authors used this evidence to suggest that apathy and depression are clinically distinct 
neuropsychiatric syndromes.  
Levy et al. (1998) evaluated whether apathy and depression may be produced by 
different neuroanatomical or neurochemical substrates by evaluating these two symptoms 
in different diagnostic groups, including patients diagnosed with PD, AD, frontotemporal 
dementia (FTD), progressive supranuclear palsy (PSP) and Huntington’s disease (HD). 
Firstly, apathy and depression were not correlated in the combined sample. Secondly, the 
frequency of apathy and depression significantly varied across groups with a large 
number of AD, FTD, and PSP patients having apathy without depression, and many PD 
and HD patients having depression without apathy. This disparity was especially notable 
in patients with PD and PSP. Few PD patients presented with apathy alone compared to 
those who had depression with or without apathy, and few PSP patients presented with 
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depression, but a high frequency of PSP patients presented with apathy. These findings 
suggest that the relationship between apathy and depression appears to be disease-
specific.  
Landes et al. (2005) explored the differential relationship of apathy, dysphoria, 
and depression with other clinical variables (i.e., stage of disease, cognitive impairment, 
and functional impairment) in patients diagnosed with Alzheimer’s disease to provide 
support for the differentiation of apathy and mood disturbance. Their analyses revealed 
that apathy occurs more frequently than dysphoria in AD. Apathy was strongly related to 
disease severity, cognitive impairment, activities of daily living, while dysphoria was 
weakly related or unrelated to these variables. Landes et al. (2005) provided these results 
as evidence for the importance of a syndrome-based approach, with emphasis on the 
importance of distinguishing dysphoria from apathy syndrome.  
 
Apathy, Depression and Cognition 
Another method of dissociating apathy and depression as distinct constructs is to 
evaluate their independent influences on cognitive functioning. Some studies have 
revealed an effect of apathy on cognitive functioning in PD that is distinct from that of 
depression. Starkstein and colleagues (2005) demonstrated a significant association of 
apathy and global cognitive abilities, as measured with the Mini Mental Status Exam 
(MMSE), but no significant association of depression and global cognitive abilities. In 
their sample of Alzheimer’s disease patients, those with apathy had significantly more 
severe cognitive deficits than those without apathy. Levy (1998) also found that apathy 
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correlated significantly with increased cognitive impairment as measured with the MMSE 
whereas depression did not.  
To investigate depression, apathy, and cognition in a sample of patients diagnosed 
with Alzheimer’s disease, Kusiz and colleagues (1999) classified patients into four 
groups:  (1) depression-only (without apathy); (2) apathy-only (without depression); (3) 
both depression and apathy; and (4) controls with neither depression nor apathy. Patients 
meeting the DSM-IV criteria for major depression or dysthymia were considered 
depressed, whereas patients scoring more than two standard deviations above the mean 
apathy scale score were considered apathetic. Using ANOVA and post hoc t-tests to 
compare groups, Kusiz and colleagues found that patients with apathy only (without 
depression) had significantly lower scores on verbal memory and confrontational naming 
compared to patients without apathy (depression-only and control). Patients with apathy 
only (without depression) and patients with both apathy and depression had significantly 
lower scores on a dexterity task as compared to patients with neither apathy nor 
depression (controls) and had significantly lower scores on two executive measures as 
compared to patients without apathy (depression-only and control). Overall, their results 
suggest that memory and executive deficits were associated with apathy rather than 
depression.  
In a sample of non-demented older adults diagnosed with major depressive 
disorder (MDD), Feil and colleagues (2003) examined apathy, depression, and cognitive 
performance using correlations and individual stepwise regression analyses. Results of 
correlational analyses revealed significant correlations between apathy and two cognitive 
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measures: nonverbal executive (WCST-Other Responses) and processing speed (Stroop 
B). Near-significant relationships were found between apathy and two verbal executive 
measures (FAS and Stroop C). Depression was significantly correlated with two 
information processing speed measures (Stroop A and Stroop B) and near-significant 
relationships were found between depression and verbal executive performance (Stroop 
C).  
Individual stepwise regression (i.e., entry of the independent variables, IVs, is 
determined by the statistical software based on the magnitude of correlations with the 
dependent variable) was performed on the four cognitive measures that significantly 
correlated with apathy (i.e., Stroop B, Stroop C, FAS, and WCST) to determine whether 
apathy uniquely accounted for test score variance over and above that accounted for by 
depression, health status, age, and education. Regression analyses on the four IVs 
revealed that apathy alone accounted for a significant amount of test score variance on a 
nonverbal executive task (WCST; R2 = 0.13) and that apathy plus demographic variables 
together accounted for a significant amount of variance on two verbal executive measures 
(FAS and Stroop C). Specifically, education was the best predictor of one verbal 
executive measure (FAS; R2 = 0.074), followed by apathy (R2 = 0.070). Age was the best 
predictor of the second verbal executive measure (Stroop C; R2 = 0.171), followed by 
apathy (R2 = 0.100). Apathy, depression, and age together accounted for a significant 
amount of variance on a processing speed task (total R2 = 0.308). Specifically, depression 
was the best predictor of processing speed (Stroop B; R2 = 0.219), followed by age (R2 = 
0.046), then apathy (R2 = 0.043). Overall, both apathy and depression were associated 
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with some cognitive variables, but apathy was a greater influence on executive 
functioning than was depression severity.   
 
Apathy, Depression and Cognition in PD 
Only four studies have investigated depression, apathy, and cognition in a sample 
of patients diagnosed with PD using a more extensive battery of neurocognitive 
assessments (Starkstein et al., 1992a; Isella et al., 2002; Pluck and Brown, 2002; 
Aarsland et al., 1999). All four studies revealed a significant relationship between apathy 
and cognitive impairment, particularly in executive functioning.  
Starkstein and colleagues (1992a) examined correlates of apathy, depression, and 
cognition by comparing PD patients with apathy only, depression only, apathy plus 
comorbid depression, and neither depression nor apathy (control subjects). This research 
team found that the patients with apathy (with or without depression) showed 
significantly more deficits on time-dependent executive tasks (specifically, poorer verbal 
fluency/executive as measured by FAS and slower performance on Trail Making Test B), 
whereas depressed patients showed significantly more deficits in an untimed executive 
task (i.e., Wisconsin Card Sorting Task, WCST). Both apathy and depression were 
significantly associated with impaired episodic verbal memory.  
Aarsland and colleagues (1999) found a significant correlation between apathy 
and number of errors on the Stroop test, a measure of executive functioning. This 
relationship was not found between depression and cognition or between apathy and 
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depression, suggesting that the relationship between apathy and cognitive decline is not 
due to depression. 
Isella and colleagues (2002) compared PD patients with low, moderate, and high 
levels of apathy and found a clear association between apathy and executive functioning, 
with the high-apathy group showing significantly greater impairment in executive 
functioning [i.e., Executive Interview (EXIT), letter fluency and category fluency] 
compared to the other two groups. Depression was not significantly correlated with 
apathy or any cognitive abilities measured. The research group did not, however, 
examine the independent influence of depression on cognitive abilities. 
Pluck and Brown (2002) found similar results showing that apathy, but not 
depression, was related to deficits in global cognitive ability (especially on the memory 
and language subscales) and on three measures of executive functioning (i.e., category 
fluency, Stroop Color-Word test, and WCST). A series of exploratory regression analyses 
demonstrated that, while none of the clinical or demographic variables (age, sex, 
education, duration of illness, Hoehn and Yahr stage or Schwab and England score) 
predicted apathy ratings, category fluency and Stroop Interference were the best 
predictors of apathy scores.   
Overall, these studies suggest that apathy and depression are independent clinical 
phenomena that negatively affect memory, language, and executive functioning. Further, 
they suggest that apathy may account for cognitive deficits over and above that of 
depression, particularly in the cognitive domain of executive functioning.  
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Limitations of Previous Research 
 Although several studies have examined the relationships between apathy, 
depression, and cognitive functioning in patients with neurological conditions (e.g., 
Alzheimer’s disease, Frontotemporal Dementia, and Huntington’s disease), only four 
have examined specific domains of neurocognitive impairment in patients diagnosed with 
PD. The few studies have examined these relationships are limited in several ways.  
 First, many have used measures of apathy and/or depression with questionable 
ability to measure symptoms unique to the target construct. Symptom overlap hinders 
discriminability among constructs. For instance, Starkstein et al. (1992a) used the 
Hamilton Depression Rating Scale (HDRS), a widely used measure that has been accused 
of being a weak index of depressive severity due to poor content validity and a 
multidimensional factor structure (Gibbons, Clark, and Kupfer, 1993; Bagby, Ryder, 
Schuller, and Marshall, 2004). Aarsland et al. (1999) used the Neuropsychiatric Inventory 
(NPI; Cummings et al., 1994), a measure commonly used in dementia to measure 
dysphoria, apathy, and anxiety, among several other neuropsychiatric disturbances. 
Factor analysis of the NPI showed that apathy and anxiety existed together on one factor, 
revealing that the NPI measures shared symptoms of apathy and anxiety.  
Pluck and Brown (2002) measured depressive symptoms using the Beck 
Depression Inventory (BDI; Beck, Ward, Mendelson, et al., 1961), which includes 
numerous somatic items that overlap with symptoms of PD itself. Use of such measures 
may artificially inflate depressive symptom severity in medical populations (Taylor, 
Lovibond, Nicholas, Cayley, and Wilson, 2005).  
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In the present study, the Apathy Evaluation Scale – self-rating form (AES-S; 
Marin, 1991), a scale specifically designed to discriminate apathy from depression, will 
be used to measure apathetic symptoms. The self-rating version of the AES was chosen 
based on the consideration that motivation is an internal state that informants may not be 
able to adequately assess. Further, informants may have difficulty distinguishing between 
emotional symptoms of apathy (i.e., unchanging affect) and “masked facies,” a common 
deficit in PD patients that refers to decreased facial expression. A multitrait-multimethod 
matrix procedure was used to support the convergent validity and discriminant validity of 
the AES-S (Marin, 1991). While apathy scales, such as the AES, have been designed to 
discriminate between apathy and depression, no depression scales have been developed 
with the intent to eliminate symptoms that overlap with apathy. 
 The present study will utilize select items from the Beck Depression Inventory – 
II (BDI-II) in an attempt to assess a continuum of depressive symptoms that do not 
overlap with apathy symptoms or with somatic symptoms of PD itself. A total of 13 
items will be retained from the BDI-II that assess the same content domains as identified 
in cognitive/affective scale of the BDI-I. Use of the full BDI-II is not ideal for a PD 
population since many of these patients may experience somatic symptoms that are 
unrelated to depression (Taylor et al., 2005). Items corresponding to the 
cognitive/affective scale of the BDI-I will be retained (e.g., sadness, pessimism, sense of 
failure, etc.) with the exception of the item related to lack of interest due to its possible 
overlap with apathy. Items that correspond to the somatic/behavior scale of the Beck 
Depression Inventory – I (BDI-I) (e.g., sleep disturbance, appetite, tiredness/fatigability, 
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etc.) will be eliminated to protect against artificial inflation of depressive symptom 
severity.  
 As mentioned above, most studies investigating the relationships between 
depression, apathy, and cognition have used measures of global cognitive ability (e.g., 
MMSE), rather than measures assessing specific cognitive domains. The present study 
will examine verbal memory and executive functioning, two cognitive abilities that have 
shown to be associated with depression, apathy, and PD.  
 Lastly, most of the studies described above have used correlational analyses and 
ANOVAs with post-hoc comparisons, with the exception of two (Pluck and Brown, 
2002; Feil et al., 2003). While such designs are elegant in their ability to evaluate 
emotional and cognitive differences among groups of individuals, they do not provide 
information regarding the degree to which apathy or depression influences cognition over 
and above the other. In the present study, hierarchical regression analyses will allow for 
investigation of the influence of depression on cognitive performance while controlling 
for the independent influence of apathy, and vice versa.  
 
Purpose of the Proposed Study 
The purpose of this study is to examine the independent influence of depression and 
apathy on cognitive functioning (specifically, memory and executive functioning) in PD 
patients. Depression is the most common psychiatric symptom in PD and has been shown 
to be associated with cognitive deficits. Apathy, a symptom related to motivational and 
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self-initiation impairment, is also prevalent in PD and has gained recent attention in this 
population.  
Several studies have demonstrated evidence to suggest that apathy and depression 
are independent clinical phenomena. Recent research suggests that apathy may account 
for cognitive deficits over and above that of depression. However, few studies have 
examined the independent influence of depression and apathy on cognitive abilities in 
patients diagnosed with PD. The majority of these studies have used simple screening 
measures of global cognitive ability that are insensitive to specific cognitive abilities, 
such as executive functioning and verbal memory. In addition, only two studies have 
examined these relationships using hierarchical regression, only one of which was in a 
PD population. Hierarchical regression allows us to pit apathy and depression against 
each other in a test that provides an estimate of the degree of influence that depression 
has on cognitive performance while controlling for the independent influence of apathy, 
and vice versa  
 
Hypotheses/Predictions 
 It is hypothesized that increased levels of depression and apathy will be associated 
with   decreased performance on measures of executive and memory abilities. This 
hypothesis will be examined in two ways: magnitude of correlation coefficients and 
hierarchical regression. It is predicted that 1) significant negative correlations will 
observed between measures of depression/apathy and executive/memory abilities and 2) 
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depression and apathy will significantly predict level of executive and memory abilities 
when entered as the first variable in hierarchical regression analyses.   
It is hypothesized that apathy will be more strongly associated with executive 
functioning than depressive symptoms. This hypothesis will also be examined in two 
ways: magnitude of correlation coefficients and hierarchical regression. Using 
correlational analyses and Hotelling’s t-test to compare correlations, it is predicted that 
the correlation between apathy and executive functioning will be significantly greater 
than the correlation between depression and executive functioning. Using hierarchical 
regression, it is predicted that apathy will account for a significant proportion of added 
variance in executive functioning scores over and above that accounted for by depression 
alone, but that depression will not account for a significant proportion of added variance 
in executive functioning scores over and above that accounted for by apathy alone. 
Examination of additional findings from regression analyses will also afford 
exploration of possible independent effects of apathy and depression on memory abilities 
although hypotheses and predictions for this variable are less clear based on prior 
literature.   
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2. Method 
Participants 
Sixty-eight individuals (44 men, 24 women) diagnosed with idiopathic, non-
fluctuating PD, ages 56-82, were included in the present study. Number of participants 
required was determined by a priori power analysis using G-Power computer program 
(Faul and Erdfelder, 1992). Sixty-eight participants was needed to yield a power of 0.80 
given a medium effect size of d = 0.15.  All participants were recruited from Movement 
Disorder clinics of the University of South Florida Parkinson’s Disease Center of 
Excellence and monthly PD support group meetings in the Tampa Bay area. 
Patients with atypical Parkinson’s disease (i.e., known cause, including previous 
exposure to toxins or atypical presentation of symptoms), early onset PD, or current or 
past history of other neurological disorder, cardiac arrest, psychiatric disturbance (other 
than depression or anxiety), or head injury with loss of consciousness were excluded 
from participation. In addition, patients scoring below 24 on the Mini-Mental Status 
Exam were excluded from participation. All patients were tested during the “on” phase, 
when medication is effective and motor symptoms are reduced.   
 
Measures 
Beck Depression Inventory – II (BDI-II). The BDI-II (Beck, Steer, and Brown, 
1996) is a 21-item self-report instrument intended to assess the existence and severity of 
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depressive symptoms consistent with the depression criteria of the Diagnostic and 
Statistical Manual of Mental Disorders – 4th Edition (DSM-IV; 1994). BDI-II items are 
scored on a four-point Likert scale (0-3), with statements arranged to represent increasing 
intensity of a particular symptom of depression. For the purposes of this study, the 
following 13 items of the BDI-II will be used as a measure of depressive symptom 
severity: Sadness, Pessimism, Past Failure, Loss of Pleasure, Guilty Feelings, Punishment 
Feelings, Self-dislike, Self-criticalness, Suicidal Thoughts or Wishes, Crying, 
Indecisiveness, Worthlessness, and Irritability (see Appendix A). This well-established 
measure and has excellent reliability and validity. One-week test-retest reliability was 
reported as r = 0.93 (Beck et al., 1996) and internal consistency across studies is excellent 
(α = 0.89 – 0.94) (Dozois and Covin, 2004). Evidence for construct validity has stemmed 
from several factor analyses (Dozois and Covin, 2004) and convergent, discriminant, and 
content validity are well-supported (e.g., Beck et al, 1996; Osman et al., 1997; Dozois 
and Covin, 2004). 
Apathy Evaluation Scale – Self-Rating (AES-S) and Informant-Rating (AES-I). 
The AES-S (Marin, 1991) is an 18-item self-rating scale that was developed to assess 
apathetic symptoms within behavioral, cognitive, and emotional domains (see Appendix 
B). Items are scored on a four point Likert scale (1 = “Not at all true”; 2 = “Slightly true”; 
3 = “Somewhat true”; 4 = “Very true”) and scoring is arranged so that higher scores 
represent greater apathy. This has been used in a number of clinical groups, including PD 
and has been found to have good construct validity, internal consistency (α = 0.86) and 
test-retest reliability (α = 0.76) (Marin et al., 1991). Multitrait-multimethod matrix 
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procedures show support for convergent and discriminant validity (Marin, et al, 1991). 
The AES-I is a parallel measure completed by a relative/spouse who has regular contact 
with the research participant in order to provide an outside perspective. This was 
administered when possible in order to investigate informant ratings, however, the AES-S 
was used for analyses. 
Mini Mental State Exam (MMSE). The MMSE (Folstein, Folstein, and McHugh, 
1975) is an 11-item examination and the most widely used cognitive screening test. 
Research provides widespread support for its validity in assessing global cognitive status. 
Each item assesses one of the following domains: orientation to time, orientation to place, 
registration, attention, recall, naming, repetition, comprehension, reading, writing, and 
drawing. Patients scoring less than 24 will be excluded from the study to avoid confounds 
of significant cognitive impairment, which may affect patients’ ability to validly 
complete self-report measures.  
Wisconsin Card Sorting Test-64 (WCST-64). The WCST-64 (Kongs, Thompson, 
Iverson, and Heaton, 2000) is a shortened version of the Wisconsin Card Sorting Test, 
Revised and Expanded (WCST; Heaton, Chelune, Talley, Kay, and Curtiss, 1993), one of 
the most widely used measures of executive functioning. The test provides detailed 
feedback regarding specific aspects of problem-solving abilities, such as inefficient initial 
conceptualization, perseveration, failure to maintain a cognitive set, and inefficient 
learning. In this task, subjects are required to match 64 cards to one of four target cards. 
Matching rules are color, shape/form, or number of symbols. Subjects infer these rules 
from feedback about whether the match was correct, which is provided by the tester 
31 
 
immediately following the match. After ten consecutive correct matches, the tester 
changes the rule without preannouncement. The Number of Categories Completed score 
will be selected for the present analysis as it reflects the ability to shift set from one 
activity to the next. Past research shows that PD patients are particularly sensitive to this 
type of task (eg., Cools, Barker, Sahakian, and Robbins, 2001). The WCST-64 has 
excellent interscorer and intrascorer reliability (0.88-0.93 and 0.91-0.96, respectively) 
(Paolo et al., 1996; Axelrod, Goldman, and Woodard, 1992), and has demonstrated 
sensitivity to executive impairment in PD, Alzheimers disease, and in individuals who 
have suffered frontal lobe injury (e.g., Paolo et al., 1996; Robinson, Heaton, Lehman, and 
Stilson, 1980). 
Hopkins Verbal Learning Test-Revised (HVLT-R). The HVLT-R (Benedict, 
Schretlen, Groninger, Brandt, 1998) is a verbal learning and memory test that consists of 
a list of 12 words, each belonging to one of three semantic categories. There are three 
immediate memory trials, one delayed recall trial (20-25 minutes after completion of the 
third immediate memory trial), and a recognition trial. The Total Recall score, which is 
the sum of the three immediate memory trials, will be selected for the present analysis 
because prior research shows that PD patients have more pronounced impairments on 
immediate memory tasks compared to delayed memory tasks (Sagar et al., 1988). 
Literature supports the reliability of the HVLT-R (e.g., six-week test-retest reliability for 
Total Recall is 0.74 in healthy elderly) (Benedict et al., 1998) as well as construct 
discriminative, and predictive validity. Shapiro and colleagues (1999) demonstrated that 
HVLT Total Recall was correlated with a prose verbal memory test (i.e., Logical 
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Memory) at r = 0.75, showed 95% sensitivity and 83% specificity, had a positive 
predictive value of 0.84, and a negative predictive value of 0.94.).  
 
Procedure 
Eligible participants were recruited from the Department of Neurology and 
Movement Disorders Clinics at the University of South Florida and from support group 
meetings in the Tampa Bay area. Patients were invited to participate by clinic 
neurologists during regular patient visits or by a research assistant on the present study. 
Diagnosis and staging of PD was determined by board-certified neurologists using the 
Hoehn and Yahr scale (1967), a standard staging scale commonly used in PD research. 
After giving informed consent, participants were screened with the MMSE to 
ensure that they met basic cognitive requirements. Those with an MMSE score below 24 
were excluded from further participation. Next, included participants were asked to 
complete a series of self-report measures to determine their affective status. Some 
participants completed these questionnaires after their appointment and returned them by 
mail within one week of participation. A memory test was then administered by the 
primary investigator, followed by a test of executive functioning.  
 
Statistical Analyses 
Two approaches were used to examine the relationship between cognitive 
functioning (memory and executive functioning) and psychological symptom severity 
(depression and apathy) in the present study: (1) correlation coefficients, and (2) 
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regression analyses. First, correlation coefficients were calculated between psychological 
and cognitive variables, revealing a total of four correlation coefficients (i.e., 1. executive 
function and depression, 2. executive function and apathy, 3. memory and depression, 4. 
memory and apathy).  
Hierarchical regression analyses were then conducted to compare the degree of 
influence that depression and apathy have on cognitive impairment. Executive function 
and memory served as criterion variables and were evaluated independently. In the two 
hierarchical regression analyses of executive ability, the independent effects of depression 
and apathy on executive functioning were assessed.  In the first hierarchical regression 
analysis, the selected items of the BDI-II were entered to account for the influence of 
depressive symptoms. Finally, the AES-S was entered, leaving a final change in R2 that 
reflects the amount of variance in executive functioning that is accounted for by apathy 
above and beyond the influence of depression (i.e., while controlling for the effects of 
depression). In the second hierarchical regression analysis of executive ability, the AES-S 
was entered to account for the influence of apathy symptoms. Finally, the selected items 
of the BDI-II were entered, leaving a final change in R2 that reflects the amount of 
variance in executive functioning that is accounted for by depression above and beyond 
the influence of apathy (i.e., while controlling for the effects of apathy).   
The same two hierarchical regression analyses were repeated to assess the 
independent influence of depression and apathy on memory. The final R2 in both 
hierarchical regression analyses reflects the amount of variance in memory that is 
accounted for by the independent influence of depression or apathy. 
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3. Results
Diagnostics 
SPSS 15.0 for Windows was used to manage and analyze data. Prior to 
conducting analyses to investigate the above stated hypotheses, data point distributions 
were examined for significant departures from normality and data was examined to 
ascertain that regression assumptions were met. Examination of boxplots and 
standardized residuals confirmed that data points of interest fell within acceptable limits 
(+/- 3 standard deviations from the mean) for analysis. Cook’s d (range: 0.000 – 0.218), 
hat values (range: 0.004 – 0.174), and Mahalanobis distance (range: 0-.256 – 11.672) 
values revealed that no individual cases were producing undue influence on the 
regression model. Examination of boxplots and descriptive statistics confirmed the 
absence of skewness and kurtosis among the variables. Scatterplots of regression 
standardized residuals and predicted values verified the assumptions of homoscedasticity 
and linearity. The inspection of VIF (all values ≤ 1.466) and tolerance statistics (all 
values ≥ 0.682), eigenvalues and variance proportions, as well as correlation coefficients 
between predictors (r < 0.60) revealed that the assumption of no multicollinearity was 
met. Durbin-Watson statistic values (range: 1.729 – 2.545) fell within acceptable limits, 
supporting the assumption of independent errors. 
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Descriptives 
Data was obtained from 68 Parkinson’s disease patients between the ages of 56 
and 82 years (mean = 69.96, SD = 7.03). Subjects were majority male (n = 45, 66.2%) 
and Caucasian (n = 63; 92.6%), Education level ranged from 12-22 years (mean = 15.74, 
SD = 2.62). All patients were in the mild to moderate stages of diseases (Hoehn and Yahr 
Stages 1-3). Depression severity ranged from no symptoms of depression to moderate 
levels and apathy severity ranged from no apathy symptoms to severe levels. Cognitive 
performance ranged from better than expected to severe impairment. A summary of 
demographic, clinical, and experimental variables from this sample is provided in Tables 
1 and 2.  
 
Table 1: Summary of demographic and clinical characteristics 
 Range Mean (SD) 
Age 
 
56 - 82 69.96 (7.03) 
Years of education 
 
12 - 22 15.74 (2.62) 
Disease duration 
(yrs) 
<1 - 24 7.07 (4.96) 
 
 n % 
Gender 
     Male 
     Female 
 
 
45 
23 
 
66.2 % 
33.8 % 
Ethnicity 
     White 
     Black 
     Hispanic 
 
 
63 
1 
4 
 
92.6 % 
1.5 % 
5.9 % 
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Table 1 (Continued) 
 n % 
Stage of disease 
          1 
          2 
          3 
        data not obtained  
 
15 
33 
9 
11 
 
22.1 % 
48.5 % 
13.2 % 
16.2 % 
 
Side of onset 
          R 
          L 
        data not obtained  
 
 
32 
31 
5 
 
 
47.1 % 
45.6 % 
7.4 % 
 
 
 
Table 2: Summary of mood and cognitive scores including age-adjusted T-scores  
 Raw scores T-scores 
Range Mean 
(SD) 
Range Mean 
(SD) 
Depression 
(21-item BDI) 
 
0-23 10.62 
(5.26) 
37-76 44.75 
(9.16) 
Depression 
(13-item BDI) 
 
0-14 4.10 
(3.49) 
-- -- 
Apathy 
(AES-S) 
 
18-50 30.29 
(7.51) 
34-84 46.57 
(11.73) 
Imm Memory* 
(HVLT Total Recall) 
 
8-33 21.31 
(5.84) 
20-70 43.34 
(10.97) 
Executive Fx** 
(WCST Categories) 
0-5 2.06 
(1.71) 
17-64 38.75 
(10.06) 
     
* T-scores adjusted for age and education 
** T-scores adjusted for age 
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Correlation analyses were used to evaluate the relationships between demographic 
and clinical variables (i.e., age, years of education, disease duration), and experimental 
variables (i.e., depression, apathy, memory, executive functioning) (see Table 3). Raw 
scores were used in all correlation and regression analyses. Increasing age was 
significantly associated with decreases in memory and executive performance (r = -
0.279, p < 0.01 and r = -0.312, p < 0.05, respectively). Years of education and disease 
duration were not associated with cognitive performance.  
 
Table 3: Correlations 
 Depression  
(21-item 
BDI) 
Depression 
(13-item 
BDI) 
Apathy  
(AES-S) 
Memory 
(HVLT 
Total Recall) 
Executive Fx 
(WCST 
Categories) 
Age 
 
.303** 0.189ns 
 
.233t -0.279* -0.312** 
Education 
 
0.022ns 0.086ns 0.150ns -0.026ns 0.053ns 
Disease 
duration 
-0.056ns -0.096ns -0.061ns 0.111ns 0.158ns 
* p<0.05 **p<0.01 ttrend, p<0.10  ns not significant, p>0.10 
 
 
Frequencies of apathy and depression 
The frequency of apathy, using AES-S ≥ 38 as representative of clinically 
significant elevations in apathy (Pluck and Brown, 2002; Rabkin, Ferrando, van Gorp, et 
al., 2000), was 20%. This rate appears to be lower than reported frequencies of apathy in 
other studies using self-ratings (Kirsch-Darrow, Fernandez, Marsiske, Okun, and Bowers, 
2006) and may be due to measurement differences or to the restricted range of disease 
severity in the present sample, as all of our participants were in the mild to moderate 
38 
 
stages of disease. When using the more commonly used BDI cut-off score of 10, the 
frequency of mild or greater depressive symptoms was 52%, which is similar to 
percentages reported in previous studies (e.g., Brooks and Doder, 2001; Cummings, 
1992). When using a cut-off score of 16/18, suggested for more accurate identification of 
diagnosable depression in mild to moderate PD patients (Silberman et al., 2006; 
Leentjens, Verhey, Luijckx, and Troost, 2000), the frequency of depression was 13.3%. 
The majority of patients with depression severity scores above this cut-off were in the 
mild range and fewer fell within the moderate range.  
Based on AES and BDI cut-off scores of 38 and 18, respectively, patients in 
present study were assigned to four categories for frequency analyses (i.e., apathy-only, 
depression-only, apathy and depression, and no apathy or depression). The majority of 
patients (72.1%) were classified as neither apathetic nor depressed, whereas 14.7% of 
patients were classified as apathy-only, 7.4% as depression-only, and 5.9% as apathy and 
depression. 
 
Findings related to Hypothesis #1 
To investigate the hypothesis that increased levels of depression and apathy will 
be associated with decreased performance on measures of executive and memory 
abilities, four correlation coefficients and four simple regressions were examined. 
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Correlations 
Table 4 displays the results of correlation analyses. Increases in depressive 
symptoms were associated with decreases in memory scores (r = -0.273, p < 0.05) but 
were not significantly associated with executive functioning. Increases in apathy 
symptoms were associated with decreases in both memory (r = -0.331, p < 0.01) and 
executive functioning (r = -0.305, p < 0.05). Apathy and depressive symptoms were 
positively and moderately correlated (r = 0.548, p < 0.01).  
 
Table 4: Correlations between mood and cognitive variables 
Variable Depression 
(13-item BDI) 
Apathy  
(AES-S) 
Memory 
(HVLT Total 
Recall) 
Executive Fx 
(WCST 
Categories) 
Depression 
 
1.000 
 
  
Apathy 
 
.548** 1.000   
Memory  
 
-.273* -.331** 1.000  
Executive Fx -.141ns -.305* .478** 1.000 
* p<0.05 **p<0.01 ns not significant, p=.251 
 
 
 
Regressions 
These relationships are corroborated by four simple regression analyses, in which 
level of depressive symptoms or apathy symptoms were entered as the sole independent 
variable (IV) and memory or executive functioning was entered as the sole dependent 
variable (DV) (see Table 5). First, it was found that level of depressive symptoms 
significantly predicted memory scores (ß = -.273, t(66) = -2.309, p < 0.05), with 7.5% of 
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the variance explained (R2 = .075, F(1,66) = 5.331, p < 0.05). Second, level of depressive 
symptoms did not significantly predict executive functioning scores, as evidenced by a 
non-significant ß value (ß not significantly different from 0) and a non-significant F 
value. The third simple regression revealed that level of apathy symptoms significantly 
predicted memory scores (ß = -.331, t(66) = -2.849, p < 0.01), with 10.9% of the variance 
explained (R2 = .109, F(1,66) = 8.115, p < 0.01). The final simple regression revealed 
that level of apathy significantly predicted scores of executive functioning (ß = -.305, 
t(66) = -2.602, p < 0.05), with 9.3% of the variance explained (R2 = .093, F(1,66) = 
6.770, p < 0.05). 
 
Table 5: Simple regression analyses 
Criterion Predictor SB T Sig T R2 F Sig F 
Memory 
 
Depression -.273 -2.309 .024* .075  5.331 .024* 
Exec. Fx 
 
Depression -.141 -1.158 .251 .020 1.341 .251 
Memory 
 
Apathy -.331 -2.849 .006** .109 8.115 .006** 
Exec. Fx. Apathy -.305 -2.602 .011* .093 6.770 .011* 
* p<0.05 **p<0.01 
SB=Standardized Beta 
 
 
 
Findings related to Hypothesis #2 
To investigate the hypothesis that apathy will be more strongly associated with 
executive functioning than depressive symptoms, two correlation coefficients (1. 
correlation between executive functioning and depression, and 2. correlation between 
executive functioning and apathy) and two hierarchical regressions were examined.  
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Correlations 
As mentioned above (see Table 4), executive functioning was significantly 
correlated with apathy (r = -.305, p < 0.05), but not with depression (r = -.141, p = .251). 
Due to the non-significant correlation between executive functioning and apathy, the 
proposed Hotelling’s t-test to compare correlations was not conducted.  
 
Regressions 
Examination of the first hierarchical regression analysis reveals the influence of 
apathy on executive functioning scores while controlling for the influence of depressive 
symptoms (see Table 6-A). In this analysis, depression (IV) is entered in the regression 
first and apathy (IV) is entered second to assess whether apathy contributed unique 
variance in accounting for executive performance above and beyond that of depressive 
symptoms. As noted above, depressive symptoms did not account for any significant 
portion variance in executive performance when entered alone. However, the addition of 
apathy reveals that apathy accounts for 9.4% of the variance in executive performance, 
with a significant change in the value of the F-test with the addition of this variable (R2 = 
.094, p <0.05; F(1,65) = 3.372, p < 0.05).  
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Table 6-A: Hierarchical regression analyses related to executive functioning 
 
Criterion 
 
Predictor 
Unstandard.  
   beta         SE 
 
SB 
 
R2 
 
R2? 
 
F? 
 
Sig F?
Exec. Fx (Constant) 
Depression 
Apathy 
4.229 
.018 
-.074 
.875 
.069 
.032 
-- 
.037 
-.325
-- 
.020 
.094 
-- 
.020 
.074 
-- 
1.341 
5.315 
-- 
.251 
.024* 
* p<0.05 **p<0.01 
SE=Standard Error; SB=Standardized Beta 
 
 
Age effects. Due to the fact that age was significantly correlated with the DV 
(executive functioning) and was approaching significance (p = 0.056) when correlated 
with one of the IVs (apathy), age was entered into regression equations first in order to 
control for its influence on executive functioning (see Table 6-B). Following the entry of 
age, apathy was entered to assess its unique influence on executive functioning while 
controlling for age. Depression was not entered into this model due to the nonsignificant 
relationship between depression and executive functioning described above, and to the 
potential unfavorable effect that entering three predictors may have on power.  Analyses 
revealed that age accounted for 9.7% of the variance in executive performance and 
apathy accounted for an additional 5.7% of the variance in executive performance.  
 
 
Table 6-B: Hierarchical regression analyses related to executive functioning, controlling 
for age 
 
 
Criterion 
 
Predictor 
Unstandard.  
   beta         SE 
 
SB 
 
R2 
 
R2? 
 
F? 
 
Sig F? 
Exec. Fx (Constant) 
Age 
Depression 
Apathy 
8.245 
-.063 
.029 
-.063 
2.029 
.029 
.067 
.032 
-- 
-.258 
.060 
-.278
-- 
.097 
.104 
.157 
-- 
.097 
.007 
.053 
-- 
7.095 
.510 
3.989 
-- 
.010** 
.478 
.050* 
* p<0.05 **p<0.01 
SE=Standard Error; SB=Standardized Beta 
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Ancillary Analyses 
Exploration of the Influence of Apathy and Depression on Memory 
In order to explore the independent effects of apathy and depression on memory 
abilities, two additional hierarchical regressions were conducted and examined. 
Examination of the first hierarchical regression analysis reveals the influence of apathy 
on memory scores while controlling for the influence of depressive symptoms (see Table 
7-A). In this analysis, depression (IV) is entered in the regression first and apathy (IV) is 
entered second to assess whether apathy contributed unique variance in accounting for 
memory performance above and beyond that of depressive symptoms. As noted 
previously, depression accounts for 7.5% of the variance in memory scores when entered 
first into the regression. The addition of apathy reveals that apathy accounts for an 
additional 4.7% of unique variance in memory performance, as evidenced by a change in 
the value of the F-test that approaches significance with the addition of this variable (R2 
= .122; R2 change = .047, p = .067; F(1,65) = 4.499, p < .05).  
For exploratory purposes, a second regression analysis was conducted to evaluate 
the influence of depressive symptoms on memory performance while controlling for the 
influence of apathy (see Table 7-A). In this analysis, apathy was entered in the first step 
and depression was entered second to assess whether depression contributed unique 
variance in accounting for memory performance above and beyond that of apathy 
symptoms. As noted previously, apathy accounts for 10.9% of the variance in memory 
scores when entered first into the regression. The addition of depression reveals that 
depression does not account for any additional or unique variance in memory scores over 
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and above that of apathy, as evidenced by a non-significant ß value (ß not significantly 
different from 0) and a non-significant F value.  
 
Table 7-A: Hierarchical regression analyses related to immediate memory  
 
Criterion 
 
Predictor 
Unstandard.  
   beta         SE 
 
SB 
 
R2 
 
R2? 
 
F? 
 
Sig F?
Memory 
 
 
(Constant) 
Depression 
Apathy 
28.308 
-.220 
-.201 
2.943 
.232 
.108 
-- 
-.132 
-.259
-- 
.075 
.122 
-- 
.075 
.047 
-- 
5.331 
3.467 
-- 
.024* 
.067t 
Memory 
 
 
(Constant) 
Apathy 
Depression 
28.308 
-.201 
-.220 
2.943 
.108 
.232 
-- 
-.259 
-.132
-- 
.109 
.122 
-- 
.109 
.012 
-- 
3.115 
.896 
-- 
.006** 
.347 
* p<0.05 **p<0.01 ttrend, p<0.10 
SE=Standard Error; SB=Standardized Beta 
 
 
 
Age effects. Due to the fact that age was significantly correlated to the DV 
(memory) and was approaching significance (p = 0.056) when correlated with one of the 
IVs (apathy), age was entered into regression equations first in order to control for its 
effect on memory (see Table 7-B). Following the entry of age, depression was entered 
second and apathy was entered last. Analyses revealed that age accounted for 7.8% of the 
variance in memory performance (p = 0.02), depression accounted for an additional 5.1% 
of the variance in memory performance (p = 0.057), and apathy no longer accounted for a 
significant portion of additional variance in memory performance (R2 change = 3.3%, p = 
0.116). Considering the p-value associated with the entry of apathy last (p = 0.116), it is 
quite possible that the reduction in power caused by entering a third predictor variable 
into the model (power = 0.75) may have resulted in the inability to adequately identify a 
significant R2 change when apathy was entered as the third variable. Interestingly, when 
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apathy was entered into the regression analysis before depression, level of apathy 
symptoms significantly accounted for an additional 7.5% of the variance in memory 
performance (p = 0.02), after accounting for the influence of age. In this order of 
operations, level of depressive symptoms no longer accounted for a significant portion of 
additional variance in memory performance (R2 change = 0.9%, p = 0.411), consistent 
with the two-predictor model described previously, which did not include age in the 
model. 
 
 
Table 7-B: Hierarchical regression analyses related to immediate memory, controlling for 
age 
 
 
Criterion 
 
Predictor 
Unstandard.  
   beta         SE 
 
SB 
 
R2 
 
R2? 
 
F? 
 
Sig F?
Memory 
 
 
(Constant) 
Age 
Depression 
Apathy 
39.261 
-.171 
-.190 
-.172 
6.907 
.098 
.229 
.108 
-- 
-.206 
-.114 
-.221
-- 
.078 
.128 
.162 
-- 
.078 
.051 
.033 
-- 
5.573 
3.767 
2.534 
-- 
.021* 
.057t 
.116 
Memory 
 
 
(Constant) 
Age 
Apathy 
Depression 
39.261 
-.171 
-.172 
-.190 
6.907 
.098 
.229 
.108 
-- 
-.206 
-.221 
-.114
-- 
.078 
.153 
.162 
-- 
.078 
.075 
.009 
-- 
5.573 
5.733 
.685 
-- 
.021* 
.020* 
.411 
* p<0.05 **p<0.01 ttrend, p<0.08 
 SE=Standard Error; SB=Standardized Beta 
 
 
 
Use of the 21-item versus 13-item Version of the BDI-II 
All analyses described above included an altered version of the BDI-II (13-item 
BDI) as the measure of total depressive symptoms, which excluded somatic and apathy-
related items in order to reduce potential confounds of these items on the measure of 
depression. Comparisons were made between regression analyses that used the 13-item 
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BDI-II and the full 21-item BDI-II in order to assess whether the decision whether or not 
to include somatic and apathy-related items in the measurement of depressive symptoms 
would result in disparate findings. Notably, when the full 21-item BDI-II was included in 
the regression analyses (i.e., 1. memory regressed on apathy and depression, 2. executive 
functioning regressed on depression and apathy) in place of the 13-item version, results 
were comparable. In addition, there was little difference in the correlations between 
apathy and depression severity regardless of whether the full 21-item version or the 
altered 13-item version was used in the analysis (r = 0.548 versus r = 0.563, 
respectively). These findings suggest that the omission of “overlapping” somatic and 
apathy-related items from the BDI for the purpose of measuring symptoms unique to 
depression may not be beneficial. 
 
Use of Informant-Ratings versus Self-Ratings of Apathy 
  Comparisons were made between regression analyses that used the AES self-
rating form (AES-S) and the informant-rating form (AES-I) in order to assess whether the 
source of this information would have an effect on the findings. In the regression 
analyses that included executive functioning as the DV, results were comparable 
regardless of whether the AES-S or AES-I was used. In the regression analyses that 
included memory as the DV, results were also comparable with the use of the AES-I 
except that the added influence of apathy over and above that of depression reached full 
statistical significance (p < 0.05) as opposed to being a trend. 
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4. Discussion 
The purpose of the present study was to examine the independent influence of 
depression and apathy on immediate memory and executive functioning in PD patients 
using sensitive measures of cognitive performance as well as rating scales that assess 
symptoms unique to depression and apathy. Due to the potential confounds of including 
somatic and apathy-related items in the measurement of depression severity, only BDI-II 
items corresponding to the cognitive/affective scale were retained (e.g., sadness, 
pessimism, sense of failure, etc.), with the exception of the item related to lack of interest 
due to its overlap with apathy. In other words, all somatic and apathy-related items from 
the full BDI-II were eliminated in order to create the modified version of the BDI-II used 
in the present study. Further, the AES was chosen to measure apathy severity due to its 
purported ability to discriminate between apathy and depression.  
 
Effects of Apathy and Depression on Memory and Executive Ability 
In the present study, two hypotheses were investigated. First, it was hypothesized 
that increased levels of depressive symptoms and increased levels of apathy would be 
associated with decreased performance on measures of executive and memory abilities. 
In support of this hypothesis, apathy negatively correlated with memory and executive 
functioning in correlation analyses and level of apathy predicted level of memory and 
executive functioning in regression analyses. The hypothesis was further supported in 
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that depression negatively correlated with memory performance in correlation analyses 
and level of depression predicted level of memory in regression analyses. Surprisingly, 
however, a relationship between depression and executive functioning was not identified. 
The correlation between level of depressive symptoms and executive functioning was not 
significant. While it was predicted that the magnitude of the relationship between apathy 
and executive functioning would be significantly larger than that of the relationship 
between depression and executive functioning, the lack of a significant correlation 
between depression and executive function was unexpected. Notably, the lack of 
association between these variables remained when the full 21-item BDI-II was included 
in secondary analyses, demonstrating that the lack of relationship between depression 
severity and executive functioning was not explained by the exclusion of somatic and 
apathy-related items or by the consequent reduction in range of scores.  
  
Unique Effects of Apathy and Depression on Executive Function 
Second, it was hypothesized that apathy would be more strongly associated with 
executive functioning than depressive symptoms as demonstrated by the magnitude of the 
correlation coefficients and by a significant R2 change when apathy was entered last in a 
hierarchical regression analysis. This hypothesis was supported. Increases in apathy, but 
not depression, were significantly associated with decreases in executive performance. 
Hierarchical regression analyses revealed that apathy, and not depression, accounted for a 
significant proportion of added variance in executive functioning. When controlling for 
age, this finding remained. 
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It is possible that the relationship between depression and executive function may 
be a small effect, and that the present study did not have an adequate number of 
participants, and hence power, to detect that relationship. While the number of 
participants in the present study (n = 68) is adequate for detecting a medium effect size 
with power of 0.80, this would not have been enough subjects to detect a small effect. 
Alternatively, using a shortened version of the BDI-II may have restricted the range of 
scores on this measure of depressive symptoms. However, this is unlikely for a couple of 
reasons. First, the lack of association remained when using the full version of the BDI-II 
as when using the shortened, modified version. Second, a relationship was identified 
between level of depressive symptoms (i.e., as measured using the shortened BDI-II) and 
memory, indicating that the memory analyses were not hindered by restriction of range. 
Regardless, the finding that the relationship between depression and executive function is 
not significant in the present study, but that the relationship between apathy and 
executive function is significant, supports the notion that apathy has a greater influence 
than depression on executive impairment in patients with Parkinson’s disease.  
The present findings are consistent with other studies reporting similar results. 
Pluck and Brown (2002) found that apathy, but not depression, was associated with 
deficits on three measures of executive functioning (i.e., category fluency, Stroop Color-
Word test, and WCST). Isella and colleagues (2002) found that PD patients with high-
apathy showed significantly greater impairment in executive functioning [i.e., Executive 
Interview (EXIT), letter fluency and category fluency] when compared to low- and 
moderate-apathy groups. Significant correlations were identified between apathy and 
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executive functioning while depression was not significantly associated with apathy or 
any cognitive abilities measured. Similarly, Aarsland and colleagues (1999) identified a 
significant association between executive functioning and apathy but not between 
executive functioning and depression or between apathy and depression. 
 
Unique Effects of Apathy and Depression on Memory 
Finally, exploratory analyses were conducted to investigate the possible 
independent effects of apathy and depression on immediate memory abilities. As stated 
above, levels of both apathy and depressive symptoms were similarly correlated with 
memory performance. Hierarchical regression analyses were used to investigate the 
degree of influence that apathy has on memory performance when controlling for 
depression and the degree of influence that depression has on memory performance when 
controlling for apathy. Our findings suggest that while depression does not predict 
memory scores over and above that of apathy, apathy revealed a strong trend to predict 
memory over and above that of depression (i.e., p = .067).  
When controlling for age, the findings became less clear. It is important to note 
that by choosing to investigate the effects of apathy and depression on memory while 
controlling for age, power was reduced to 0.75 due to the addition of a third independent 
variable (i.e., age) into the regression equation. A closer look at the p-values associated 
with entering either depression or apathy as the third variable (refer to Table 7-B) reveals 
that when age is controlled for, apathy likely remains as a significant predictor of 
memory scores over and above that of depression (p = .116). In contrast, it is unlikely 
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that depression is a significant predictor of memory scores over and above that of apathy 
(p = .411). A larger sample is needed to test whether this is, in fact, accurate, since there 
was insufficient power to investigate the influence of three independent variables given 
the sample size in this investigation. An alternative explanation for this finding is that, 
despite our attempts to use measures that assess non-shared aspects of apathy and non-
shared aspects of depression, our measurement did not fully discriminate. This raises 
question regarding the construct validity of the scales used and begs further investigation 
into definitions and assessments of apathy.  
 
Conclusion 
Overall, the findings of the present study suggest that apathy and depression may 
exert unique effects on memory and executive function.  These findings provide support 
for the notion of apathy and depression as discernable constructs. First, apathy and 
depression were differentially related to cognitive performance, most strongly in the 
domain of executive functioning. Second, the frequencies of clinical elevations of apathy 
and depression in the present sample also support the notion that apathy and depression 
can be considered as distinguishable constructs, with clinically elevated apathy symptoms 
existing in the absence of clinically elevated depressive symptoms. The presence of 
clinically elevated apathy in the absence of depression has been even more convincingly 
and consistently in Alzheimers disease, frontotemporal dementia, progressive 
supranuclear palsy, and basal ganglia stroke (e.g., Levy et al., 1998; Starkstein et al., 
2005).  
52 
 
While unique aspects of depression and apathy may explain their differential 
influence on executive functioning, shared factors may underlie their relationship with 
memory. Potential shared mechanisms may include frontostriatal circuitry, reduced 
processing speed, anergia, avolition, and the emotional concomitants of apathy (e.g., 
anhedonia). While most of the apathy literature is consistent in defining apathy by 
behavioral and cognitive dimensions, opinions differ on whether definitions should 
include an emotion dimension (Starkstein and Leentjens, 2007). According to a 
preliminary study of patients with dementia, anhedonia is rarely reported in patients who 
report apathy but no depression, suggesting that anhedonia may be more characteristic of 
depression than apathy (SE Starkstein, personal communication; as cited in Starkstein 
and Leentjens, 2007).  
 
Theoretical Implications 
Differentiation of apathy and depression and understanding their independent 
effects has several implications both for clinical treatment and for scientific pursuit. First, 
apathy appears to be negatively associated with cognitive functioning, daily functioning, 
and caregiver burden and distress (van Reekum et al., 2005). Secondly, apathy has been 
associated with increased morbidity and mortality. Apathetic patients devote less 
attention and time to self-care, which can result in medical complications. Additionally, it 
may interfere with treatment response and medication compliance and has been 
associated with increased mortality and financial burden (Stephenson, 2005; van Reekum 
et al., 2005). 
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Further, due to the absence of reported or exhibited distress, patients suffering 
from apathy are often overlooked by the health care system. There is currently a bias in 
health care favoring diagnosing depression (Schulman, 2000). Cognizance of apathy in 
patients seeking health care services may help to prevent false positive diagnoses of 
depression and may increase efficiency in timely and adequate treatment of patients 
experiencing apathy and not depression. Additionally, making caregivers aware of the 
prevalence of apathy in Parkinson’s disease, among other neuropsychiatric or neurologic 
diseases, may help them understand that related behaviors are not due to insolence or 
laziness but, rather, to a disease-related neurologic changes.  
Identification of apathy may be improved by the inclusion of apathy in psychiatric 
classification systems. Currently, apathy is underrepresented in such classification 
systems. Apathy is not referenced in the ICD-10 (WHO, 1993) and is only mentioned 
specifically in relation to four disorders of the DSM-IV (APA, 1994), with no inclusion 
of the term “apathy” in the DSM-IV glossary. Discussion regarding differential diagnosis 
and on whether apathy should appear as a stand-alone disorder in the Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) has begun (Stephenson, 
2005). If not included as a stand-alone disorder, potential improvements of the status of 
apathy, including clarifying the definition of apathy, adding apathy to the glossary of the 
DSM, or creating a reference to help direct clinicians to the range of disorders commonly 
associated with apathy, are being considered by DSM-IV Editor, Michael B. First, MD 
(Stephenson, 2005).  
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If appropriately identified, preliminary research suggests that symptoms of apathy 
may be medically or behaviorally treated independently of depressive symptoms. For 
example, Weitzner and colleagues (2005) described four cases of pituitary disease 
patients who were diagnosed and medically treated for depression but showed little 
response to treatment. When the diagnosis of apathy syndrome was considered and 
treatment with methylphenidate was implemented, the patients’ condition improved 
subjectively and on objective cognitive tasks. Further, Hoehn-Saric, Lipsey, and McLeod 
(1990) found that apathy and indifference followed treatment with select antidepressant 
serotonin-reuptake-inhibitors. Notably, these were not randomly, controlled medication 
trials, which would be a great benefit to the apathy treatment literature.  
Behavioral treatments may also provide benefit to patients experiencing 
disruptive levels of apathy. Boyle and Malloy (2004) have suggested that caregivers may 
be able to play an important role in behavioral training programs aimed at reducing 
apathy in patients with Alzheimer’s disease. By definition, apathy involves the lack of 
motivation and initiation. Caregivers may promote behavioral activation by helping 
patients initiate goal-directed behaviors, increasing their involvement in pleasant 
activities, and providing increased structure for activities.  
Future research elucidating the effectiveness of caregiver-involved behavioral 
interventions, as well as randomized controlled medication trials, on patients with 
elevated levels of apathy is warranted. In addition, future studies aimed at understanding 
the neural underpinnings of depression and apathy may help guide more effective choices 
of pharmacological and/or behavioral management of these symptoms. Further 
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investigation into the relationship between apathy and fluctuating on/off periods in PD 
patients, in which levels of dopamine are adequate or limited in the brain, may provide 
interesting information regarding the underlying neurotransmitter effects.  
Differentiation of apathy and depression has robust implications for the 
advancement of psychological science and patient care. The utility of investigating 
symptoms of apathy and depression, as opposed to solely clinical diagnoses, is evident in 
that even some level of symptomatic apathy and depression appears to influence 
efficiency of patients’ cognitive abilities. A focus on apathy symptoms in patients may 
optimize treatment approaches, improve patients’ daily functioning, increase 
independence, and result in an improved quality of life for both patients and their 
caregivers.    
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Appendices 
 
Appendix A: Beck Depression Inventory – II  
(Note: Items used for the 13-item modified version are highlighted) 
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Appendix B: Apathy Evaluation Scale – Self-Rating form 
For each question, circle the answer that best describes your 
thoughts, feelings and actions during the past 4 weeks. 
 
 
1. I am interested in things. 
Not at All 
0 items 
1 
Slightly 
1-2 items 
2 
Somewhat 
2-3 items 
3 
Very 
3 or more items 
4 
 
2. I get things done during the day. 
Not at All 
0 items 
1 
Slightly 
1-2 items 
2 
Somewhat 
2-3 items 
3 
Very 
3 or more items 
4 
 
3. Getting things started on my own is important to me. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
4. I am interested in having new experiences. 
Not at All 
0 items 
1 
Slightly 
1-2 items 
2 
Somewhat 
2-3 items 
3 
Very 
3 or more items 
4 
 
5. I am interested in learning new things. 
Not at All 
0 items 
1 
Slightly 
1-2 items 
2 
Somewhat 
2-3 items 
3 
Very 
3 or more items 
4 
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6. I put little effort into anything. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
7. I approach life with intensity. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
8. Seeing a job through to the end is important to me. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
9. I spend time doing things that interest me. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
10. Someone has to tell me what to do each day. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
11. I am less concerned about my problems than I should be. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
12. I have friends. 
Not at All 
0 items 
1 
Slightly 
1-2 items 
2 
Somewhat 
2-3 items 
3 
Very 
3 or more items 
4 
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13. Getting together with friends is important to me. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
14. When something good happens, I get excited. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
15. I have an accurate understanding of my problems. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
16. Getting things done during the day is important to me. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
17. I have initiative. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
18. I have motivation. 
Not at All 
Characteristic 
1 
Slightly 
Characteristic 
2 
Somewhat 
Characteristic 
3 
A Lot 
Characteristic 
4 
 
